Physician profile
Cecilia Chanda
NPI 1154904183
$4,539.82
in general payments reported to CMS, 2019-2025
16 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $445 · 2023: $1,249 · 2024: $1,481 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,033 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,033.49 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,033.62 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $793.38 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $520.68 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $358.79 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $293.57 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $285.09 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $264.99 | 2023-2025 | Spravato |
| Alkermes, INC. | $218.66 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $179.57 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $134.97 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $133.87 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $120.25 | 2024-2025 | Cobenfy |
| Brainsway USA INC | $101.71 | 2025 | Deep Tms System |
| Tris Pharma INC | $38.22 | 2024-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $33.29 | 2025 | Jornay Pm |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $29.16 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecilia Chanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.